Peter J.M. Valk

Erasmus MC — Netherlands

Medicine · Health Sciences

73h-index25.0kcitations502works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(334), Myeloproliferative Neoplasms: Diagnosis and Treatment(65), Protein Degradation and Inhibitors(62), Epigenetics and DNA Methylation(61), Chronic Myeloid Leukemia Treatments(58)

Publications501 total

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia
Leukemia·2026Open Access
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study
Leukemia·2026Open Access
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities
Blood Advances·2026Open Access
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party
Blood·2025· 1 citedOpen Access
A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia
Leukemia·2025Open Access
Data for "Drivers of Clinical Resistance to Venetoclax and Hypomethylating agents in Acute Myeloid Leukemia and Strategies for Improving Efficacy"
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Data for "Drivers of Clinical Resistance to Venetoclax and Hypomethylating agents in Acute Myeloid Leukemia and Strategies for Improving Efficacy"
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
Blood·2025· 1 cited
Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries
Blood·2025
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials
Blood·2025· 1 citedOpen Access
The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy
Blood·2025
Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials
Blood·2025Open Access
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Leukemia·2025Open Access
Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
HemaSphere·2025· 2 citedOpen Access
Utility of <i>IDH1/2</i> mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia
Blood Advances·2025· 3 citedOpen Access
A revised prognostic model for patients with acute myeloid leukemia and first relapse
Blood Advances·2025Open Access
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Haematologica·2025· 1 citedOpen Access
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Blood·2025· 27 citedOpen Access
Treatment‐Free Remission Outcomes in a <i><scp>BCR</scp>::<scp>ABL1</scp></i> Digital <scp>PCR</scp> Selected Clinical Cohort of <scp>CML</scp> Patients
European Journal Of Haematology·2025· 2 citedOpen Access
Single-cell DNA sequencing reveals pervasive positive selection throughout preleukemic evolution
Cell Genomics·2025· 4 citedOpen Access
page 1 of 26Next →

Frequent Co-authors

Bob Löwenberg(37), Ruud Delwel(26), Claudia Erpelinck-Verschueren(14), H. Berna Beverloo(10), Mathijs A. Sanders(10), Konstanze Döhner(10), Lars Bullinger(9), Ari Melnick(7), Gert J. Ossenkoppele(7), Bas J. Wouters(7), María E. Figueroa(6), Sanne Lugthart(6), Mojca Jongen‐Lavrencic(6), Thomas Pabst(6), Hartmut Döhner(5), Wim L.J. van Putten(5), Roel G.W. Verhaak(4), Tim Grob(4), Jacqueline Cloos(4), Bart J. Biemond(4)